Assess whether scientific advice should be sought before the next trial

SITUATION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — scientific-advice briefing book — after a CRL citing manufacturing, not efficacy. If scientific-advice briefing book cannot support scientific advice should be, the only defensible Pharma & Life Sciences output is hold.

DECISION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Pediatric-plan strategist can defend Proceed under protocol from scientific-advice briefing book after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge. 2. Pediatric-plan strategist cannot defend Proceed under protocol from scientific-advice briefing book; Pause the pathway is what the extract actually supports after a CRL citing manufacturing, not efficacy. 3. A CRL citing manufacturing, not efficacy never reached the population in scientific-advice briefing book — reopen intake, do not close scientific advice should be. 4. Two facts in scientific-advice briefing book after a CRL citing manufacturing, not efficacy conflict for pediatric-plan strategist; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether scientific-advice briefing book supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in scientific-advice briefing book, then the action for pediatric-plan strategist - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT